US Food and Drug Administration officials may want to use new draft guidance to strike a more authoritative tone about extensions of ANDA complete response letter deadlines, but sponsors may not see much change from current practices.
The draft guidance, released 28 September, suggests that the agency may no longer “liberally” grant extension requests. The number...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?